Amplyx Pharmaceuticals acquired by Pfizer

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

Amplyx closes $53 million Series C extension

Amplyx advances development of novel antifungal, fosmanogepix

Amplyx unveils expanded pipeline and reports Phase 2 data from lead programme

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals